Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Methicillin-Resistant Staphylococcus aureus HELP
Based on 8,920 articles since 2006
||||

These are the 8920 published articles about Methicillin-Resistant Staphylococcus aureus that originated from Worldwide during 2006-2015.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline [Practical guidelines for the management and treatment of infections caused by MRSA, the 2nd Edition]. 2014

Niki, Yoshihito / Anonymous920800. · ·Kansenshogaku Zasshi · Pubmed #25672136.

ABSTRACT: -- No abstract --

2 Guideline A compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates. 2014

Yokoe, Deborah S / Anderson, Deverick J / Berenholtz, Sean M / Calfee, David P / Dubberke, Erik R / Ellingson, Katherine D / Gerding, Dale N / Haas, Janet P / Kaye, Keith S / Klompas, Michael / Lo, Evelyn / Marschall, Jonas / Mermel, Leonard A / Nicolle, Lindsay E / Salgado, Cassandra D / Bryant, Kristina / Classen, David / Crist, Katrina / Deloney, Valerie M / Fishman, Neil O / Foster, Nancy / Goldmann, Donald A / Humphreys, Eve / Jernigan, John A / Padberg, Jennifer / Perl, Trish M / Podgorny, Kelly / Septimus, Edward J / VanAmringe, Margaret / Weaver, Tom / Weinstein, Robert A / Wise, Robert / Maragakis, Lisa L / Anonymous4570786. ·Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. · ·Infect Control Hosp Epidemiol · Pubmed #25026611.

ABSTRACT: Since the publication of "A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals" in 2008, prevention of healthcare-associated infections (HAIs) has become a national priority. Despite improvements, preventable HAIs continue to occur. The 2014 updates to the Compendium were created to provide acute care hospitals with up-to-date, practical, expert guidance to assist in prioritizing and implementing their HAI prevention efforts. They are the product of a highly collaborative effort led by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), the American Hospital Association (AHA), the Association for Professionals in Infection Control and Epidemiology (APIC), and The Joint Commission, with major contributions from representatives of a number of organizations and societies with content expertise, including the Centers for Disease Control and Prevention (CDC), the Institute for Healthcare Improvement (IHI), the Pediatric Infectious Diseases Society (PIDS), the Society for Critical Care Medicine (SCCM), the Society for Hospital Medicine (SHM), and the Surgical Infection Society (SIS).

3 Guideline Strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in acute care hospitals: 2014 update. 2014

Calfee, David P / Salgado, Cassandra D / Milstone, Aaron M / Harris, Anthony D / Kuhar, David T / Moody, Julia / Aureden, Kathy / Huang, Susan S / Maragakis, Lisa L / Yokoe, Deborah S / Anonymous3880783. ·Weill Cornell Medical College, New York, New York. · ·Infect Control Hosp Epidemiol · Pubmed #24915205.

ABSTRACT: -- No abstract --

4 Guideline "Preoperative risk management: strategy for Staphylococcus aureus preoperative decolonization" (2013 update). French society of Hospital Hygiene. 2014

Lepelletier, D / Saliou, P / Lefebvre, A / Lucet, J-C / Grandbastien, B / Bruyère, F / Stahl, J-P / Keita-Perse, O / Berthelot, P / Aho, S / Anonymous3900784. ·Service de bactériologie et d'hygiène hospitalière, CHU de Nantes, 44000 Nantes, France; Société française d'hygiène hospitalière, France. Electronic address: didier.lepelletier@chu-nantes.fr. · Service d'hygiène hospitalière, CHU de Brest, 29000 Brest, France; Société française d'hygiène hospitalière, France. · Service d'épidémiologie et d'hygiène hospitalière, CHU de Dijon, 21000 Dijon, France; Société française d'hygiène hospitalière, France. · Unité hospitalière de lutte contre l'infection nosocomiale, hôpital Bichat-Claude-Bernard, AP-HP, 75018 Paris, France; Société française d'hygiène hospitalière, France. · Service de gestion du risque infectieux, des vigilances et d'infectiologie, CHRU de Lille, 59000 Lille, France; Société française d'hygiène hospitalière, France. · Service d'urologie, hôpital Bretonneau, CHRU de Tours, 37000 Tours, France. · Service des maladies infectieuses et tropicales, CHU de Grenoble, 38000 Grenoble, France. · Service d'hygiène hospitalière, hôpital Princesse Grâce, 44000 MC98012, France; Société française d'hygiène hospitalière, France. · Unité d'hygiène inter-hospitalière, service des maladies infectieuses, laboratoire de microbiologie, CHU de Saint-Étienne, 42000 Saint-Étienne, France; Société française d'hygiène hospitalière, France. · ·Med Mal Infect · Pubmed #24835378.

ABSTRACT: -- No abstract --

5 Guideline Clinical practice guidelines for therapeutic drug monitoring of arbekacin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. 2014

Okada, Kenji / Kimura, Toshimi / Mikamo, Hiroshige / Kasahara, Kei / Seki, Masafumi / Takakura, Shunji / Tokimatsu, Issei / Ohmagari, Norio / Takahashi, Yoshiko / Matsumoto, Kazuaki / Igarashi, Masahiro / Kobayashi, Masahiro / Hamada, Yukihiro / Mochizuki, Takahiro / Kimura, Masao / Nishi, Yoshifumi / Tanigawara, Yusuke / Takesue, Yoshio / Anonymous4760773 / Anonymous4770773. ·Department of Pharmacy, Tokyo Women's Medical University Hospital, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan. · Department of Infection Control and Prevention, Aichi Medical University, Graduate School of Medicine, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan. · Center for Infectious Diseases, Nara Medical University, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan. · Division of Infection Control and Prevention, Osaka University Medical Hospital, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan. · Department of Infection Control and Prevention, Kyoto University Hospital, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan. · Internal Medicine II, Oita University Faculty of Medicine, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan. · Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan. · Department of Pharmacy, Hyogo Medical College Hospital, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan. · Department of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan. · Department of Pharmacy, Toranomon Hospital, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan. · Department of Pharmacy, Kitasato University Hospital, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan. · Department of Infection Control and Prevention, Aichi Medical University, Graduate School of Medicine, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan. · Department of Pharmacy, Shizuoka Cancer Center, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan. · Department of Pharmacy, Aichi Medical University Hospital, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan. · Department of Pharmacy, Kyorin University School of Medicine, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan. · Keio University, School of Medicine, Department of Clinical Pharmacokinetics and Pharmacodynamics, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan. · Department of Infection Control and Prevention, Hyogo Medical College Hospital, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan. Electronic address: karyo@jc4.so-net.ne.jp. · ·J Infect Chemother · Pubmed #24486168.

ABSTRACT: Arbekacin (ABK) was approved and widely used in Japan for treatment of patients infected with MRSA, and TDM was introduced in clinical practice. The Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring decided to develop a clinical practice guidelines for TDM of ABK for the following reasons. First, although the daily dose of 150-200 mg was approved in Japan, recent PK-PD studies revealed that higher serum concentration is required to achieve better clinical efficacy and several findings concerning the usefulness of higher dosage regimen have obtained recently. Second, although maximal concentrations that obtained immediately after the end of administration (Cmax) was generally adopted, the serum concentration at 1 h after initiation of administration [peak serum concentration (Cpeak)] proved to be more suitable as an efficacy indicator of aminoglycosides. Lastly, as ABK is approved only in Japan, no international practice guideline for TDM has not been available in ABK to date. This guideline evaluated the scientific data associated with serum ABK monitoring and provided recommendations based on the available evidence. Potential limitations of this guideline, however, include the findings that few prospective clinical trials of TDM of ABK are available in the treatment of MRSA infections and that most of the published literature describes observational studies.

6 Guideline Dutch guideline on the laboratory detection of methicillin-resistant Staphylococcus aureus. 2014

Kluytmans-van den Bergh, M F Q / Vos, M C / Diederen, B M W / Vandenbroucke-Grauls, C M J E / Voss, A / Kluytmans, J A J W / Anonymous2240771. ·Amphia Academy Infectious Disease Foundation, Amphia Hospital, Breda, The Netherlands, marjoleinkluytmans@gmail.com. · ·Eur J Clin Microbiol Infect Dis · Pubmed #23893016.

ABSTRACT: Methicillin-resistant Staphylococcus aureus (MRSA) has rapidly emerged worldwide, affecting both healthcare and community settings, and intensive livestock industry. The efficient control of MRSA strongly depends on its adequate laboratory detection. This guideline provides recommendations on the appropriate use of currently available diagnostic laboratory methods for the timely and accurate detection of MRSA in patients and healthcare workers. Herewith, it aims to standardise and improve the diagnostic laboratory procedures that are used for the detection of MRSA in Dutch medical microbiology laboratories.

7 Guideline [Practical guidelines for the management and treatment of infections caused by MRSA]. 2013

Niki, Yoshihito / Aoki, Nobuki / Iwata, Satoshi / Kishida, Shuji / Kobayashi, Masahiro / Sato, Junko / Anonymous6300767. · ·Kansenshogaku Zasshi · Pubmed #24483017.

ABSTRACT: -- No abstract --

8 Guideline Guidelines for the treatment of methicillin-resistant Staphylococcus aureus infections in Taiwan. 2013

Chen, Yao-Sheng. ·yschen@vghks.gov.tw ·J Microbiol Immunol Infect · Pubmed #23768761.

ABSTRACT: -- No abstract --

9 Guideline Diagnosis and treatment of Staphylococcus aureus infections of the skin and mucous membranes. 2011

Schöfer, Helmut / Bruns, Roswitha / Effendy, Isaak / Hartmann, Martin / Jappe, Uta / Plettenberg, Andreas / Reimann, Holger / Seifert, Harald / Shah, Pramod / Sunderkötter, Cord / Weberschock, Tobias / Wichelhaus, Thomas A / Nast, Alexander / Anonymous1920700 / Anonymous1930700 / Anonymous1940700 / Anonymous1950700 / Anonymous1960700. · ·J Dtsch Dermatol Ges · Pubmed #22026364.

ABSTRACT: -- No abstract --

10 Guideline Diagnosis and management of skin and soft-tissue infections (SSTI): a literature review and consensus statement on behalf of the Italian Society of Infectious Diseases and International Society of Chemotherapy. 2011

Esposito, S / Bassetti, M / Borre', S / Bouza, E / Dryden, M / Fantoni, M / Gould, I M / Leoncini, F / Leone, S / Milkovich, G / Nathwani, D / Segreti, J / Sganga, G / Unal, S / Venditti, M / Anonymous4120699 / Anonymous4130699. ·Department Infectious Diseases, University Naples, Italy. · ·J Chemother · Pubmed #22005055.

ABSTRACT: Skin and soft-tissue infections (SSTIs) are among the most common bacterial infections, posing considerable diagnostic and therapeutic challenges and resulting in significant morbidity and mortality among patients as well as increased healthcare costs. eight members of the SSTI working group of the Italian Society of infectious Diseases prepared a draft of the statements, grading the quality of each piece of evidence after a careful review of the current literature using MEDLINE database and their own clinical experience. Statements were graded for their strength and quality using a system based on the one adopted by the Infectious Diseases Society of America (IDSA). The manuscript was successively reviewed by seven members of the SSTI working group of the international Society of Chemotherapy, and ultimately re-formulated by all e xperts. the microbiological and clinical aspects together with diagnostic features were considered for uncomplicated and complicated SSTIs. Antimicrobial therapy was considered as well -both empirical and targeted to methicillin-resistant Staphylococcus aureus (MRSA) and/or other main pathogens.

11 Guideline Preventing methicillin-resistant Staphylococcus aureus transmission in long-term care facilities: an executive summary of the APIC Elimination Guide. 2011

Rebmann, Terri / Aureden, Kathy / Association for Professionals in Infection Control and Epidemiology, ?. ·Institute for Biosecurity, St. Louis University, School of Public Health, MO, USA. rebmannt@slu.edu · ·Am J Infect Control · Pubmed #21367490.

ABSTRACT: This article is an executive summary of the APIC Elimination Guide for methicillin-resistant Staphylococcus aureus infection in long-term care facilities. Infection preventionists are encouraged to obtain the original, full-length APIC Elimination Guides for more thorough coverage of methicillin-resistant Staphylococcus aureus prevention in long-term care facilities.

12 Guideline Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. 2011

Liu, Catherine / Bayer, Arnold / Cosgrove, Sara E / Daum, Robert S / Fridkin, Scott K / Gorwitz, Rachel J / Kaplan, Sheldon L / Karchmer, Adolf W / Levine, Donald P / Murray, Barbara E / J Rybak, Michael / Talan, David A / Chambers, Henry F. ·Department of Medicine, Division of Infectious Diseases, University of California-San Francisco, San Francisco, California 94102, USA. catherine.liu@ucsf.edu · ·Clin Infect Dis · Pubmed #21217178.

ABSTRACT: Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures.

13 Guideline Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. 2011

Liu, Catherine / Bayer, Arnold / Cosgrove, Sara E / Daum, Robert S / Fridkin, Scott K / Gorwitz, Rachel J / Kaplan, Sheldon L / Karchmer, Adolf W / Levine, Donald P / Murray, Barbara E / J Rybak, Michael / Talan, David A / Chambers, Henry F / Anonymous2350679. ·Department of Medicine, Division of Infectious Diseases, University of California-San Francisco, San Francisco, California94102, USA. catherine.liu@ucsf.edu · ·Clin Infect Dis · Pubmed #21208910.

ABSTRACT: Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures.

14 Guideline [Treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in Latin America]. 2010

Luna, Carlos M / Rodríguez-Noriega, Eduardo / Bavestrello, Luis / Gotuzzo, Eduardo / Anonymous4760674. ·Departmento de Medicina Interna, División de Enfermedades Pulmonares, Hospital de Clínicas, Universidad de Buenos Aires, Argentina. cymluna@fmed.uba.ar · ·Rev Chilena Infectol · Pubmed #21137164.

ABSTRACT: The global spread of MRSA means it is now a pathogen of worldwide public health concern. Within Latin America, MRSA is highly prevalent, with the proportion of S. aureus isolates that are methicillin-resistant on the rise, yet resources for managing the infection are limited. While several guidelines exist for the treatment of MRSA infections, many are written for the North American or European setting and need adaptation for use in Latin America. In this article, we aim to emphasize the importance of appropriate treatment of MRSA in the healthcare and community settings of Latin America. We present a summary of the available guidelines and antibiotics, and discuss particular considerations for clinicians treating MRSA in Latin America.

15 Guideline [Prevention strategies for methicillin-resistant Staphylococcus aureus (MRSA) infections in Latin America]. 2010

Alvarez, Carlos / Labarca, Jaime / Salles, Mauro / Anonymous4750674. ·División de Enfermedades Infecciosas, Departamento de Medicina Interna, Hospital Universitario San Ignacio y Pontificia Universidad Javeriana, Bogotá, Colombia. alvarezc@javeriana.edu.co · ·Rev Chilena Infectol · Pubmed #21137163.

ABSTRACT: After the first reports of the emergence of MRSA in the 1970s, numerous measures intended to prevent its transmission were initiated in hospitals. However, in most cases, large-scale measures failed to be implemented and the transmission of MRSA has since led to a global pandemic. Presently, doubts still remain about the best approach to prevent and control MRSA and more often than not, control measures are not implemented. Therefore, we review here the current situation in Latin America with respect to existing policies for control of MRSA, and evaluate the evidence for control measures in hospitals and the community. We look at the risk factors for infection and transmission of MRSA between hospital patients and within specific populations in the community, and at the effect of antibiotic usage on the spread of MRSA in these settings. Finally, we summarize recommendations for the prevention and control of MRSA, which can be applied to the Latin American hospital environment and community setting.

16 Guideline [Diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA) in Latin America]. 2010

Zurita, Jeannete / Mejía, Carlos / Guzmán-Blanco, Manuel / Anonymous4740674. ·Servicio de Microbiología y Tuberculosis, Hospital Vozandes, Quito, Ecuador. jzurita@hcjb.org.ec · ·Rev Chilena Infectol · Pubmed #21137162.

ABSTRACT: Strategies to monitor and control the spread of MRSA infections are dependent on accurate and timely diagnosis of MRSA in both hospital and community settings. In Latin America, significant diversity in diagnostic and susceptibility testing procedures exists at the regional, national and local levels. Various tests for S. aureus and MRSA are available in clinical settings, but the application of these techniques differs between and within countries, and quality control measures are not uniformly applied to verify diagnoses. To optimize the diagnosis of MRSA infections across Latin America, a more consistent approach is required. This may include: adoption and appropriate adaption of specific guidelines for MRSA testing, depending on local resources; establishment of a coordinated system for quality control; regional access to central reference facilities; education of medical and healthcare professionals in best practices; and development of systems to evaluate the implementation of guidelines and best practices.

17 Guideline [The changing pattern of methicillin-resistant Staphylococcus aureus clones in Latin America: implications for clinical practice in the region]. 2010

Rodríguez-Noriega, Eduardo / Seas, Carlos / Anonymous4730674. ·Hospital Civil de Guadalajara Fray Antonio Alcalde, Instituto de Patología Infecciosa y Experimental, Centro Universitario Ciencias de la Salud, Universidad de Guadalajara, Jalisco, México. idfcolima@yahoo.com · ·Rev Chilena Infectol · Pubmed #21137161.

ABSTRACT: MRSA clones belonging to the Brazilian, Pediatric, Cordobes/Chilean and New York/Japan clonal complexes are widely distributed across Latin America, although their individual distribution patterns and resistance to antimicrobial drugs are constantly changing. Furthermore, clones with increased virulence are beginning to appear more frequently both in hospital and community settings, and there is evidence that virulence factors can be transferred between hospital- and community-associated clones through recombination. These changing patterns have significant implications for clinical practice in the region. Most importantly, clinicians need to be aware of the changing antimicrobial resistance profile of circulating MRSA clones in their region in order to choose the most appropriate empiric antimicrobial therapy. Thus, regional molecular epidemiology programs are required across the region to provide accurate identification and characterization of circulating MRSA clones.

18 Guideline Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. 2009

Gould, F Kate / Brindle, Richard / Chadwick, Paul R / Fraise, Adam P / Hill, Simon / Nathwani, Dilip / Ridgway, Geoff L / Spry, Michael J / Warren, Rod E / Anonymous5260631. ·Department of Microbiology, Freeman Hospital, High Heaton, Newcastle upon Tyne, UK. kate.gould@nuth.nhs.uk · ·J Antimicrob Chemother · Pubmed #19282331.

ABSTRACT: These evidence-based guidelines are an updated version of those published in 2006. They have been produced after a literature review of the treatment and prophylaxis of methicillin-resistant Staphylococcus aureus (MRSA). The guidelines aim to complement those recently published for the antibiotic treatment of common and emerging community-onset MRSA infections in the UK. The guidelines have reviewed and updated, where appropriate, previous recommendations, taking into account any changes in the UK epidemiology of MRSA, ongoing national surveillance data and the value of new antistaphylococcal agents licensed for use in UK practice. Emerging therapies that have not been licensed for UK use are not reviewed, but their future potential role has been mentioned where deemed appropriate. Recommendations are given for the treatment of common infections caused by MRSA, elimination of MRSA from carriage sites and prophylaxis of surgical site infection.

19 Guideline [Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica]. 2009

Gudiol, Francisco / Aguado, José María / Pascual, Alvaro / Pujol, Miquel / Almirante, Benito / Miró, José María / Cercenado, Emilia / Domínguez, María de Los Angeles / Soriano, Alex / Rodríguez-Baño, Jesús / Vallés, Jordi / Palomar, Mercedes / Tornos, Pilar / Bouza, Emilio / Anonymous1940629. ·Servicio de Enfermedades Infecciosas, IDIBELL, Hospital Universitario de Bellvitge, Barcelona, España. · ·Enferm Infecc Microbiol Clin · Pubmed #19254641.

ABSTRACT: Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA) are prevalent and clinically important. The rise in MRSA bacteremia and endocarditis is related with the increasing use of venous catheters and other vascular procedures. Glycopeptides have been the reference drugs for treating these infections. Unfortunately their activity is not completely satisfactory, particularly against MRSA strains with MICs > 1 microg/mL. The development of new antibiotics, such as linezolid and daptomycin, and the promise of future compounds (dalvabancin, ceftobiprole and telavancin) may change the expectatives in this field.The principal aim of this consensus document was to formulate several recommendations to improve the outcome of MRSA bacteremia and endocarditis, based on the latest reported scientific evidence. This document specifically analyzes the approach for three clinical situations: venous catheter-related bacteremia, persistent bacteremia, and infective endocarditis due to MRSA.

20 Guideline [Establishment of the classification for severity of illness of nosocomial pneumonias based on the analysis of their actual conditions]. 2008

Anonymous3470625. · ·Nihon Kokyuki Gakkai Zasshi · Pubmed #22675771.

ABSTRACT: -- No abstract --

21 Guideline [Guidelines for the treatment on infections caused by methicillin-resistant Staphylococcus aureus]. 2008

Mensa, J / Barberán, J / Llinares, P / Picazo, Jj / Bouza, E / Alvarez-Lerma, F / Borges, M / Serrano, R / León, C / Guirao, X / Arias, J / Carreras, E / Sanz, Ma / García-Rodríguez, Ja / Anonymous1770621 / Anonymous1780621 / Anonymous1790621 / Anonymous1800621 / Anonymous1810621 / Anonymous1820621. ·Sociedad Española de Quimioterapia (SEQ), Servicio de Enfermedades Infecciosas, Hospital Clinic, Barcelona, Espana. jmensa@clinic.ub.es · ·Rev Esp Quimioter · Pubmed #19031124.

ABSTRACT: Infections due to methicillin-resistant Staphylococcus aureus (MRSA) have undergone important changes in the last five years that have influenced the choice of therapy: i) increase of their frequency in hospital-associated settings and, more recently, in community settings; ii) better knowledge of clinical implications of the pharmacokinetic and pharmacodynamic properties of vancomycin; iii) improvement of current standard methods for rapid detection of MRSA in clinical samples; iv) clear evidence that vancomycin is losing efficacy against MRSA with MIC > 1 microg/mL; and v) appearance of new antibiotics suitable for use in these infections (linezolid, daptomycin, tigecyclin). Under this situation guidelines for the treatment of common infections caused by MRSA appear to be necessary to improve the efficacy and reduce the mortality.

22 Guideline [Osteoarticular infections: therapeutic proposals of the Paediatric Infectious Diseases Group of the French Society of Paediatrics (GPIP)]. 2008

Grimprel, E / Lorrot, M / Haas, H / Pinquier, D / Parez, N / Ferroni, A / Cohen, R / Anonymous2840620. ·Groupe de Pathologie Infectieuse Pédiatrique de la Société Française de Pédiatrie, Hôpital Armand Trousseau, 26 av Dr Arnold Netter 75012 Paris, Université Pierre et Marie Curie Paris VI, France. emmanuel.gripmrel@trs.aphp.fr · ·Arch Pediatr · Pubmed #19000859.

ABSTRACT: The empiric choice of initial antibiotherapy in osteoarticular infections in infants and children must take into consideration the actual epidemiology of principal pathogens, their respective antibiotic sensitivity profile, their pharmacokinetic and pharmacodynamic properties and the results of efficacy clinical studies. After a review of recent data concerning these four major points, the Paediatric Infectious Diseases Group of the French Society of Paediatrics (GPIP) has proposed guidelines for initial recommended schemes of antimicrobial therapy in acute and non complicated osteoarticular infections in infants and children.

23 Guideline Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. 2008

Calfee, David P / Salgado, Cassandra D / Classen, David / Arias, Kathleen M / Podgorny, Kelly / Anderson, Deverick J / Burstin, Helen / Coffin, Susan E / Dubberke, Erik R / Fraser, Victoria / Gerding, Dale N / Griffin, Frances A / Gross, Peter / Kaye, Keith S / Klompas, Michael / Lo, Evelyn / Marschall, Jonas / Mermel, Leonard A / Nicolle, Lindsay / Pegues, David A / Perl, Trish M / Saint, Sanjay / Weinstein, Robert A / Wise, Robert / Yokoe, Deborah S. ·Mount Sinai School of Medicine, New York, New York, USA. · ·Infect Control Hosp Epidemiol · Pubmed #18840090.

ABSTRACT: -- No abstract --

24 Editorial Livestock-associated MRSA: innocent or serious health threat? 2015

Bosch, Thijs / Schouls, Leo M. ·Centre for Infectious Diseases Research, Diagnostics & Screening (IDS), Centre for Infectious Diseases Control (CIb), National Institute of Public Health & the Environment (RIVM), Bilthoven, The Netherlands. · ·Future Microbiol · Pubmed #25865184.

ABSTRACT: -- No abstract --

25 Editorial MRSP: prevalence in practice. 2015

Paul, Narayan Chandra. ·College of Veterinary Medicine, Washington State University, Pullman 99164, WA, USA. ·Vet Rec · Pubmed #25678519.

ABSTRACT: -- No abstract --

Next